Key Highlights
● Lifecore's third amendment with Alcon Research moves the initial term end from December 31, 2031 to December 31, 2034.
● After the initial term, the agreement renews automatically for successive 24-month periods unless proper notice is given.
● Wynnefield, Nelson Obus and Joshua Landes signed a voting and support agreement covering roughly 19.8 million shares.
● The Merger agreement dated September 27, 2026 has Hazel Merger Sub, Inc. merging into Lifecore, with Lifecore surviving.
Two separate filings dated September 29, 2026 touch Lifecore Biomedical, Inc. (NASDAQ:LFCR) The company itself filed a Form 8-K under Item 1.01 reporting a third amendment to its Supply agreement with Alcon Research, LLC, extending the contract through December 31, 2034. Separately, Wynnefield Partners Small Cap Value, L.P. I and related Wynnefield entities, together with Nelson Obus and Joshua Landes, filed an amended Schedule 13D disclosing a voting and support agreement signed in connection with a merger agreement dated September 27, 2026. The two filings cover different subjects, and neither describes the other.
The Alcon Supply Agreement
According to the 8-K, Lifecore Biomedical, LLC, a Subsidiary of the registrant, and Alcon Research entered the Third Amendment on September 24, 2026, effective November 1, 2026. The underlying agreement took effect on December 31, 2023 and was previously amended on May 2, 2024 and June 13, 2025. The new amendment moves the end of the initial term from December 31, 2031 to December 31, 2034. After that, the agreement renews automatically for successive 24-month periods unless proper notice is given.
The amendment also revises an exhibit setting out Alcon's minimum purchase obligations through 2034. The filing does not disclose the quantities or dollar amounts of those minimums, and it does not disclose pricing or termination provisions. It states that Lifecore keeps certain supply obligations under the modified agreement. Beginning November 1, 2026, Lifecore also agrees not to enter new agreements to develop, supply or manufacture products that directly compete with specific Alcon products; the filing says this does not restrict existing agreements or their renewals. Chief Financial Officer Ryan D. Lake signed the filing on September 29, 2026.
The Wynnefield Filing
The amended Schedule 13D, identified as Amendment No. 11, reports that the Wynnefield entities, Mr. Obus and Mr. Landes signed a voting and support agreement dated September 27, 2026, with the parent party to the merger and Lifecore Biomedical. The merger agreement of the same date provides for a merger subsidiary, Hazel Merger Sub, Inc., to merge with and into Lifecore, with Lifecore surviving. The materials reviewed refer to consideration that includes contingent value rights under a separate agreement, but they do not state a per-share cash price.
Under the voting agreement, the stockholders agree to vote in favor of the merger and related adjournment proposals and against competing proposals or matters that could reasonably be expected to impede the merger. They also agree not to transfer the covered shares without the parent's consent, subject to limited exceptions, and they waive appraisal rights under Section 262 of Delaware law. The agreement covers common stock and shares that could be acquired through conversion of preferred stock; the covered holdings total roughly 19.8 million shares. It ends at the earliest of the required stockholder vote, the merger's effective time, termination of the merger agreement, or a change in the board's recommendation.
A voting agreement is a commitment by particular holders, not a stockholder approval of the deal. The merger still requires the vote described in the merger agreement, and the Schedule 13D/A is not the place where the full terms are set out.
Lifecore Awaits Merger Vote and Alcon Amendment
For the Alcon contract, the amendment takes effect on November 1, 2026, and the initial term now runs to December 31, 2034. Whether minimum purchase quantities are disclosed later, for example in a financial report or exhibit, is not stated in the filing.
For the merger, the next disclosures to look for are Lifecore's own Form 8-K describing the merger agreement in full, including the consideration, conditions and termination rights, followed by proxy materials for a stockholder meeting and any regulatory filings the agreement requires.






Please wait processing your request...